Elicera Therapeutics AB (ELIC) — Cash Flow Reinvestment Rate
Latest as of December 2023:
0.00x
Elicera Therapeutics AB (ELIC) has a Cash Flow Reinvestment Rate of 0.00x as of December 2023, reinvesting Skr2.00K (capex Skr1.00K plus investments Skr-1.00K) from operating cash flow of Skr3.50 Million. Explore Elicera Therapeutics AB capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
Skr2.00K
Capex + Investments
Operating Cash Flow
Skr3.50 Million
SEK
Capital Expenditures
Skr1.00K
SEK
Annual Cash Flow Reinvestment Rate for Elicera Therapeutics AB (None–None)
Year-by-year capital reinvestment analysis for Elicera Therapeutics AB. For live market cap and broader valuation context, see Elicera Therapeutics AB market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow